An administrative law judge (ALJ) with the Drug Enforcement Administration (DEA) has officially scheduled a 10-day public hearing on the agency’s proposed plan to prohibit two different psychedelic compounds that scientists are urging them to keep legal.
ALJ Paul Soeffing has scheduled an administrative hearing that will take place from November 12 to November 22. A final meeting will take place on November 25.
The proposed rule would place 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) as Schedule I drugs under the Controlled Substances Act (CSA), making them illegal for all purposes including for research and as a medicine. The DEA made a similar attempt to ban these two substances last year, but eventually revoked the effort after a large outcry from from scientists and researchers, many who feel the substances could have medical value.
:The Drug Enforcement Administration proposes placing two phenethylamine hallucinogens, as identified in this proposed rule, in schedule I of the Controlled Substances Act”, states the DEA’s posting in the Federal Register. “This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances for one of these substances 2,5-dimethoxy-4-chloroamphetamine. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess), or propose to handle these two specific controlled substances.”
